SK8682002A3 - Use of benzopyrane substituted by benzoic acid for the production of medicament for the treatment of atherosclerosis and pharmaceutical composition - Google Patents

Use of benzopyrane substituted by benzoic acid for the production of medicament for the treatment of atherosclerosis and pharmaceutical composition Download PDF

Info

Publication number
SK8682002A3
SK8682002A3 SK868-2002A SK8682002A SK8682002A3 SK 8682002 A3 SK8682002 A3 SK 8682002A3 SK 8682002 A SK8682002 A SK 8682002A SK 8682002 A3 SK8682002 A3 SK 8682002A3
Authority
SK
Slovakia
Prior art keywords
alkyl
formula
benzyl
carboxy
phenyl
Prior art date
Application number
SK868-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Robert Joseph Aiello
Patricia-Ann Bourassa
Saralyn Lindsey
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SK8682002A3 publication Critical patent/SK8682002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK868-2002A 2001-06-28 2002-06-17 Use of benzopyrane substituted by benzoic acid for the production of medicament for the treatment of atherosclerosis and pharmaceutical composition SK8682002A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30171201P 2001-06-28 2001-06-28
US32825401P 2001-10-10 2001-10-10

Publications (1)

Publication Number Publication Date
SK8682002A3 true SK8682002A3 (en) 2004-08-03

Family

ID=26972559

Family Applications (1)

Application Number Title Priority Date Filing Date
SK868-2002A SK8682002A3 (en) 2001-06-28 2002-06-17 Use of benzopyrane substituted by benzoic acid for the production of medicament for the treatment of atherosclerosis and pharmaceutical composition

Country Status (12)

Country Link
EP (1) EP1270000A3 (fr)
JP (1) JP2003034638A (fr)
KR (1) KR20030015828A (fr)
CN (1) CN1394602A (fr)
AU (1) AU4239302A (fr)
CA (1) CA2391205A1 (fr)
CZ (1) CZ20022076A3 (fr)
HK (1) HK1049795A1 (fr)
HU (1) HUP0202114A3 (fr)
IL (1) IL150340A0 (fr)
PL (1) PL354770A1 (fr)
SK (1) SK8682002A3 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4476934B2 (ja) * 2003-04-14 2010-06-09 明治乳業株式会社 新規ペプチドおよび免疫賦活剤、機能性食品ならびに機能性食品の製造方法
AU2005266088A1 (en) * 2004-07-22 2006-02-02 Pharmacia Corporation Compositions for treatment of inflammation and pain using a combination of a COX-2 selective inhibitor and a LTB4 receptor antagonist
PT1888033E (pt) * 2005-06-09 2014-05-15 Meda Ab Método e composição para tratamento de distúrbios inflamatórios
US10336733B2 (en) 2015-11-30 2019-07-02 Merk Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
EP3383389B1 (fr) 2015-11-30 2021-04-28 Merck Sharp & Dohme Corp. Utilisation d'arylacylsulfonamides en tant qu'antagonistes de blt1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720493A1 (de) * 1987-06-20 1989-01-26 Nattermann A & Cie Arzneizubereitungen mit mikronisierten ebselen-kristallen
MX9300312A (es) * 1992-01-23 1993-07-31 Pfizer Antagonistas benzopiranicos y relacionado de ltb.
DE4228200A1 (de) * 1992-08-25 1994-03-03 Schering Ag Neue Pyridin-Derivate mit Leukotrien-B¶4¶-antagonistischer Wirkung
AU696890B2 (en) * 1994-10-13 1998-09-24 Pfizer Inc. Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4) antagonists
CA2202056A1 (fr) * 1994-10-13 1996-04-25 Mark A. Dombroski Composes de benzopyranne et composes benzo-fusionnes, leur preparation et leur utilisation comme antagonistes du leucotriene b4' (ltb4)
US6342510B1 (en) * 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
DE19636689A1 (de) * 1996-09-10 1998-03-12 Boehringer Ingelheim Kg Neue Benzamidinderivate
SK31399A3 (en) * 1996-09-16 2000-05-16 Pfizer Processes and intermediates for preparing substituted chromanol derivatives
EP0963755A3 (fr) * 1998-04-16 2001-03-14 Pfizer Products Inc. Utilisation des benzopyranes pour la prévention de rejets de graiffes
WO2000010552A2 (fr) * 1998-08-24 2000-03-02 Global Vascular Concepts, Inc. Utilisation d'agents anti-angiogeniques pour empecher la lesion des parois vasculaires
JP2003225088A (ja) * 1999-09-10 2003-08-12 Meiji Seika Kaisha Ltd ヒト・ロイコトリエンｂ４第二受容体及びそれをコードするｄｎａ
WO2001068844A2 (fr) * 2000-03-17 2001-09-20 Bayer Aktiengesellschaft Regulation du recepteur humain du leucotriene de type b4, couple a la proteine g

Also Published As

Publication number Publication date
KR20030015828A (ko) 2003-02-25
HK1049795A1 (zh) 2003-05-30
JP2003034638A (ja) 2003-02-07
HU0202114D0 (fr) 2002-09-28
AU4239302A (en) 2003-01-02
IL150340A0 (en) 2002-12-01
CA2391205A1 (fr) 2002-12-28
CZ20022076A3 (cs) 2004-05-12
HUP0202114A2 (hu) 2003-01-28
HUP0202114A3 (en) 2004-07-28
EP1270000A2 (fr) 2003-01-02
CN1394602A (zh) 2003-02-05
PL354770A1 (en) 2002-12-30
EP1270000A3 (fr) 2003-02-12

Similar Documents

Publication Publication Date Title
EP1150969B1 (fr) Derives de alpha-azacyclomethyl quinoleine pour le traitement de l'incontinence urinaire
US20120184533A1 (en) Small molecule inhibitors of parp activity
EA006371B1 (ru) Противовоспалительные конденсированные пирролокарбазолы
JP2000505810A (ja) アポｂ−分泌／ｍｔｐ阻害性アミド
TW200401768A (en) Methods of treatment with CETP inhibitors and antihypertensive agents
EP3596079B1 (fr) Dérivés de pyrazolo[1,5-a]pyrimidine à substitution aryle pharmacologiquement actifs
EP1176134A1 (fr) Ligands de recepteurs nucleaires ppar
KR102420210B1 (ko) 치환된 바이사이클릭 디하이드로피리미디논 및 호중구 엘라스타제 활성 억제제로서의 이의 용도
CN101809017A (zh) 酞嗪酮衍生物
US20040214799A1 (en) Cancerous metastasis inhibitors containing carbacyclic phosphatidic acid derivatives
WO2003077832A2 (fr) Dexanabinol et analogues de dexanabinol regulant des genes associes a l'inflammation
SK8682002A3 (en) Use of benzopyrane substituted by benzoic acid for the production of medicament for the treatment of atherosclerosis and pharmaceutical composition
US20050137251A1 (en) Dexanabinol and dexanabinol analogs regulate inflammation related genes
US7432306B2 (en) Method for preparing novel transcription factors and use
TW201623261A (zh) 掌性２，５－二取代環戊烷羧酸衍生物及其用途
CA2520377A1 (fr) Compositions de substances analogues a la migrastatine et leurs utilisations
US20050143453A1 (en) Selective preventing and therapeutic agents for progressive lesion after organic damage
US20220211653A1 (en) Compositions and methods for inhibiting blood cancer cell growth
KR101720060B1 (ko) 비닐 설폰 유도체, 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 시신경 척추염 예방 또는 치료용 약학조성물
JPH10231285A (ja) フタルイミド誘導体又はその塩、それらの製造方法及びそれらを含有する医薬組成物
JP2014156403A (ja) 置換フェナントレン化合物を有効成分とするがんを予防および／または治療するための医薬組成物
KR20040072730A (ko) 글리코겐 인산화효소 억제제의 제조를 위한 중간체
TW202237073A (zh) 官能化長鏈烴單羧酸及二羧酸及其衍生物以及其於預防或治療疾病之用途
JP2011016754A (ja) 置換フェナントレン化合物を有効成分とするがんを予防および／または治療するための医薬組成物
WO2019246427A1 (fr) Formes cristallines de composés tricycliques contenant de la pyridinone et leurs procédés de préparation et d'utilisation

Legal Events

Date Code Title Description
FC9A Refused patent application